Department of Chemistry , University of California , Berkeley , California 94720 , United States.
Department of Nutritional Sciences & Toxicology , University of California , Berkeley , California 94720 , United States.
J Am Chem Soc. 2018 Oct 24;140(42):13764-13774. doi: 10.1021/jacs.8b08014. Epub 2018 Oct 15.
Copper deficiency is implicated in a variety of genetic, neurological, cardiovascular, and metabolic diseases. Current approaches for addressing copper deficiency rely on generic copper supplementation, which can potentially lead to detrimental off-target metal accumulation in unwanted tissues and subsequently trigger oxidative stress and damage cascades. Here we present a new modular platform for delivering metal ions in a tissue-specific manner and demonstrate liver-targeted copper supplementation as a proof of concept of this strategy. Specifically, we designed and synthesized an N-acetylgalactosamine-functionalized ionophore, Gal-Cu(gtsm), to serve as a copper-carrying "Trojan Horse" that targets liver-localized asialoglycoprotein receptors (ASGPRs) and releases copper only after being taken up by cells, where the reducing intracellular environment triggers copper release from the ionophore. We utilized a combination of bioluminescence imaging and inductively coupled plasma mass spectrometry assays to establish ASGPR-dependent copper accumulation with this reagent in both liver cell culture and mouse models with minimal toxicity. The modular nature of our synthetic approach presages that this platform can be expanded to deliver a broader range of metals to specific cells, tissues, and organs in a more directed manner to treat metal deficiency in disease.
铜缺乏与多种遗传、神经、心血管和代谢疾病有关。目前解决铜缺乏的方法依赖于通用的铜补充剂,这可能导致不必要的组织中有害的非靶标金属积累,并随后引发氧化应激和损伤级联。在这里,我们提出了一种新的模块化平台,用于以组织特异性的方式输送金属离子,并以肝靶向铜补充为例证明了该策略的概念验证。具体而言,我们设计并合成了一种 N-乙酰半乳糖胺功能化载体,Gal-Cu(gtsm),作为一种携带铜的“特洛伊木马”,可以靶向肝脏定位的去唾液酸糖蛋白受体 (ASGPR),只有在被细胞摄取后才会释放铜,而细胞内的还原环境会触发载体从铜中释放出来。我们利用生物发光成像和电感耦合等离子体质谱分析相结合的方法,在肝细胞培养和具有最小毒性的小鼠模型中,建立了该试剂与 ASGPR 依赖性铜积累的关系。我们合成方法的模块化性质预示着该平台可以扩展到以更有针对性的方式将更广泛范围的金属输送到特定的细胞、组织和器官,以治疗疾病中的金属缺乏。